• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Trop Med Infect Dis . Development of an Optimized Process for Functional Recombinant SARS-CoV-2 Spike S1 Receptor-Binding Domain Protein Produced i

tetano

Editor, Senior Moderator
Trop Med Infect Dis


. 2023 Nov 16;8(11):501.
doi: 10.3390/tropicalmed8110501. Development of an Optimized Process for Functional Recombinant SARS-CoV-2 Spike S1 Receptor-Binding Domain Protein Produced in the Baculovirus Expression Vector System

Mohamed Boumaiza[SUP] 1 [/SUP], Ameni Chaabene[SUP] 1 [/SUP], Ines Akrouti[SUP] 1 [/SUP], Meriem Ben Zakour[SUP] 1 [/SUP], Hana Askri[SUP] 1 [/SUP], Said Salhi[SUP] 1 [/SUP], Wafa Ben Hamouda[SUP] 2 [/SUP], Soumaya Marzouki[SUP] 2 [/SUP], Chaouki Benabdessalem[SUP] 2 [/SUP], Melika Ben Ahmed[SUP] 2 [/SUP], Khaled Trabelsi[SUP] 1 [/SUP], Samia Rourou[SUP] 1 [/SUP]



Affiliations
Abstract

To map the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and evaluate immune response variations against this virus, it is essential to set up efficient serological tests locally. The SARS-CoV-2 immunogenic proteins were very expensive and not affordable for lower- middle-income countries (LMICs). For this purpose, the commonly used antigen, receptor-binding domain (RBD) of spike S1 protein (S1RBD), was produced using the baculovirus expression vector system (BEVS). In the current study, the expression of S1RBD was monitored using Western blot under different culture conditions. Different parameters were studied: the multiplicity of infection (MOI), cell density at infection, and harvest time. Hence, optimal conditions for efficient S1RBD production were identified: MOI 3; cell density at infection 2-3 × 10[SUP]6[/SUP] cells/mL; and time post-infection (tPI or harvest time) of 72 h and 72-96 h, successively, for expression in shake flasks and a 7L bioreactor. A high production yield of S1RBD varying between 4 mg and 70 mg per liter of crude cell culture supernatant was achieved, respectively, in the shake flasks and 7L bioreactor. Moreover, the produced S1RBD showed an excellent antigenicity potential against COVID-19 (Wuhan strain) patient sera evaluated by Western blot. Thus, additional serological assays, such as in-house ELISA and seroprevalence studies based on the purified S1RDB, were developed.

Keywords: SARS-CoV-2; Sf9 cells; cell density at infection; multiplicity of infection; receptor-binding domain; spike S1 glycoprotein.

 
Back
Top Bottom